DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Motesanib
Motesanib
Tyrosine Kinase Inhibitors and Modifications of Thyroid Function Tests
TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub
Phase II Study of Motesanib in Japanese Patients with Advanced Gastrointestinal Stromal Tumors with Prior Exposure to Imatinib Mesylate
Endoperspectives, Volume 5, Issue 2
The Effect of Different Dosing Regimens of Motesanib on the Gallbladder: a Randomized Phase 1B Study in Patients with Advanced Solid Tumors
Amendment Protocol Number: 12C0079-R Reference Number: 365732
Safety and Pharmacokinetics of Motesanib in Combination
Quantitative Modeling and Analysis of Drug Screening Data for Personalized Cancer Medicine
Factors Affecting the Pharmacology of Antibody–Drug Conjugates
The Effect of Different Dosing Regimens of Motesanib on the Gallbladder
Stembook 2018.Pdf
MM&M Takes a Detailed Look at Key Products in the Pipeline
Endocrine Oncology Thyroid Carcinoma
Repositioning of Tyrosine Kinase Inhibitors As Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
Supplemental Table 2 Revised
Multikinase Inhibitor Motesanib Enhances the Antitumor Effect of Cisplatin in Cisplatin‑Resistant Human Bladder Cancer Cells Via Apoptosis and the PI3K/Akt Pathway
Download Report
Phase 1B Study of Motesanib, an Oral Angiogenesis Inhibitor, In
Top View
Phase III Trial Failures: Costly, but Preventable Alberto Grignolo, Phd, Sy Pretorius, MD
Anticancer Drug-Induced Thyroid Dysfunction
Known Bioactive Library: Selleck Bioactive 10Mm, 3.33Mm, 1.11Mm
(12) Patent Application Publication (10) Pub. No.: US 2013/0252924 A1 Penninger Et Al
Approach to the Patient with Advanced Differentiated Thyroid Cancer
Angiokinase Inhibitors in Non-Small-Cell Lung Cancer
Treatment of Advanced Thyroid Cancer Refractory to Therapy
New Developments in Targeted Treatments
Pharmaabkommen A1 E
Obstacles to Dose Optimization in Early Stage Cancer Drug Development
Prevalence of Androgen Receptor Positivity in Triple Negative Breast
WO 2016/123581 Al 4 August 2016 (04.08.2016) P O P C T
Motesanib Inhibits Kit Mutations Associated with Gastrointestinal
In Iodine-131 Refractory Papillary Thyroid Carcinoma (IRPTC) with Or Without
Mosser Et Al Figs 190702
(12) Patent Application Publication (10) Pub. No.: US 2010/0226943 A1 Brennan Et Al
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Response and Toxicity of Small-Molecule Tyrosine Kinase Inhibitors in Patients with Thyroid Carcinoma: a Systematic Review and Meta-Analysis